Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: In vitro and in vivo evaluations

Acta Pharmacologica Sinica

Volumn 31, Issue 2, 2010, Pages 237-243

  Gao, Hui Le ^a   Pang, Zhi Qing ^a   Fan, Li ^a   Hu, Kai Li ^a   Wu, Bing Xian ^a   Jiang, Xin Guo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Blood brain barrier; Brain drug targeting; Lactoferrin; Transferrin

Indexed keywords

COUMARIN 6; COUMARIN DERIVATIVE; DRUG CARRIER; FLUORESCENT DYE; IODINE 125; POLYMERSOME LACTOFERRIN CONJUGATE; POLYMERSOME TRANSFERRIN CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SCREENING; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULE; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; SURFACE PROPERTY; TARGET ORGAN; TEMPERATURE DEPENDENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ZETA POTENTIAL;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; IODINE RADIOISOTOPES; LACTOFERRIN; MICE; PARTICLE SIZE; TISSUE DISTRIBUTION; TRANSFERRIN;

EID: 76949084271     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.199     Document Type: Article

References (38)

1. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007; 12: 54-61.
2. Pardridge WM. Drug targeting to the brain. Pharm Res 2007; 24: 1733-44.
3. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004; 104: 29-45.
4. Liu X, Chen C. Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Disc 2005; 8: 505-512
5. Hu KL, Li JW, Shen YH, Lu W, Gao XL, Zhang QZ, et al. Lactoferrinconjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Release 2009; 134: 55-61.
6. Garcia-Garcia E, Andrieux K, Gilb S, Couvreur P. Colloidal carriers and blood brain barrier (BBB) translocation: away to deliver drugs to the brain? Int J Pharm 2005; 298: 274-292
7. Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood brain barrier. Clin Pharmacokinet 2007; 46: 553-576
8. Calvo P, Gouritin B, Chacun H, Desmaële D, D'Angelo J, Noel JP. Long circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001; 18: 1157-1166
9. Nuijens JH, Berkel PHC, Schanbacher FL. Structure and biological actions of lactoferrin. J Mammary Gland Biol 1996; 3: 285-295
10. Qian ZM, Li HY, Sun HZ, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002; 54: 561-587
11. Buchanan J. A structural comparison of human serum transferrin and human lactoferrin. Biometals 2007; 20: 249-62.
12. Fillebeen C, Descamps L, Dehouck MP, Fenart L. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem 1999; 274: 7011-7017
13. Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol 2000; 20: 77-95.
14. Suzuki YA, Lopez V, Lönnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 2005; 62: 2560-75.
15. Huang RQ, Ke WL, Qu YH, Zhu JH, Pei YY, Jiang C. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci 2007; 14: 121-128
16. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 1993; 142: 1574-1585
17. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995; 92: 9603-7.
18. Grau AJ, Willig V, Fogel W, Werle E. Assessment of plasma lactoferrin in Parkinson's disease. Mov Disord 2001; 16: 131-4.
19. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993; 156: 212-217
20. Ji B, Maeda J, Higuchi M. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006; 78: 851-855
21. Discher BM, Won YY, Ege DS, Lee J, Bates FS, Discher DE, et al. Polymersomes: tough vesicles made from diblock copolymers. Science 1999; 284: 1143-1146
22. Discher DE, Eisenberg A. Polymer vesicles. Science 2002; 297: 967-973
23. Pang ZQ, Lu W, Gao HL, Hu KL, Chen J, Zhang CL, et al. Preparation and brain delivery proper ty of biodegradable polymersomes conjugated with OX26. J Control Release 2008; 128: 120-127
24. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003; 90: 323-334
25. Huwyler J, Wu DF, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93: 14164-14169
26. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77
27. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albuminconjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005; 107: 428-448
28. Bermudez H, Brannan AK, Hammer DA, Bates FS, Discher DE. Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromol 2002; 35: 8203-8208
29. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002; 233: 51-59
30. Panyam J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-coglycolide) nanoparticles. Int J Pharm 2003; 262: 1-11.
31. Hunt CA, MacGregor RD, Siegel RA. Engineering targeted in vivo drug delivery: I. The physiological and physicochemical principles governing opportunities and limitations. Pharmaceut Res 1986; 3: 333-344
32. Pepper MS, Tacchini-Cottier F, Sabapathy TK, Montesano R, Wagner EF. A model for haemangiomas and other vascular tumours. In: R Bicknell CE Lewis, N Ferrara (Eds), Tumour Angiogenesis, Endothelial Cells Transformed by Polyomavirus Middle T Oncogene. Oxford, UK, Oxford University Press, 1997; p 309-331
33. Brown RC, Morris AP, O'Neil RG. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 2007; 30: 17-30.
34. Sawyer ST, Krantz SB. Transferrin receptor number, synthesis, and endocytosis during erythropoietin-induced maturation of Friend virusinfected erythroid cells. J Biol Chem 1986; 261: 9187-9195
35. Milane A, Tortolano L, Fernandez L, Bensimon G, Meininger V, Farinotti R. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J Pharm Pharmaceut Sci 2009; 12: 209-217
36. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceut Res 2007; 24: 1759-1771
37. Schluesener HJ, Xianglin T. Selection of recombinant phages binding to pathological endothelial and tumor cells of rat glioblastoma by in vivo display. J Neurol Sci 2004; 224: 77-82.
38. Yang Y, Yang D, Schluesener HJ, Zhang Z. Advances in SELEX and application of aptamers in the central nervous system. Biomol Eng 2007; 24: 583-592